Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the ...

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic ...

In conclusion, the 2025 CDSCO draft guidelines represent a meaningful and commendable step toward global regulatory alignment ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, ...

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening ...

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, ...

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...